Format

Send to

Choose Destination
Diabet Med. 2016 Mar;33(3):391-4. doi: 10.1111/dme.12833. Epub 2015 Jul 21.

Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.

Author information

1
Grunberger Diabetes Institute, Bloomfield Hills, MI, USA.
2
Profil Mainz, Mainz, Germany.
3
Lilly USA, LLC., Indianapolis, IN, USA.
4
Eli Lilly and Company, Neuilly-Sur-Seine, France.
5
Eli Lilly and Company, Houten, The Netherlands.
6
Eli Lilly and Company, Indianapolis, IN, USA.
7
Oxford Centre for Diabetes, Endocrinology and Metabolism, and NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.

Abstract

AIMS:

To assess whether early measures of fasting blood glucose predict later glycaemic response with once-weekly dulaglutide in patients with Type 2 diabetes mellitus.

METHODS:

Post hoc analyses were conducted separately for two phase 3 studies (AWARD-5 and AWARD-1) in patients assigned to once-weekly dulaglutide. Week 2 fasting blood glucose was used as a predictor variable, and glycaemic treatment response was defined by HbA1c response based on a composite efficacy endpoint. The association between fasting blood glucose and the glycaemic response was analysed using chi-square tests.

RESULTS:

There was a strong association between fasting blood glucose < 7.9 mmol/l at week 2 and achieving the HbA1c composite efficacy endpoint at week 26 (P < 0.01). Higher fasting blood glucose at week 2, however, did not predict absence of glycaemic response and requires further assessment.

CONCLUSIONS:

Fasting blood glucose measured at 2 weeks may be an early and useful predictor of glycaemic response to once-weekly dulaglutide treatment.

PMID:
26179454
DOI:
10.1111/dme.12833
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center